This invention relates to cyclic combination therapies and regimens utilizing substituted indoline derivative compounds which are antagonists of the progesterone receptor having the general structure: ##STR1## wherein: A is O, S, or NR.sup.4 ; B is a bond between A and C.dbd.Q, or the moiety CR.sup.5 R.sup.6 ; R.sup.4, R.sup.5, R.sup.6 are independently selected from H or optionally substituted C.sub.1 to C.sub.6 alkyl, C.sub.2 to C.sub.6 alkenyl, C.sub.2 to C.sub.6 alkynyl, C.sub.3 to C.sub.8 cycloalkyl, substituted C.sub.3 to C.sub.8 cycloalkyl, aryl, or heterocyclic groups, or cyclic alkyl constructed by fusing R.sup.4 and R.sup.5 to from a 5 to 7 membered ring; R.sup.1 is selected from H, OH, NH.sub.2, C.sub.1 to C.sub.6 alkyl, substituted C.sub.1 to C.sub.6 alkyl, C.sub.3 to C.sub.6 alkenyl, substituted C.sub.1 to C.sub.6 alkenyl, alkynyl, substituted alkynyl, --COH, or optionally substituted --CO(C.sub.1 to C.sub.3 alkyl), --CO(aryl), --CO(C.sub.1 to C.sub.3 alkoxy), or --CO(C.sub.1 to C.sub.3 aminoalkyl) groups; R.sup.2 is selected from H, halogen, CN, NO.sub.2, or optionally substituted C.sub.1 to C.sub.6 alkyl C.sub.1 to C.sub.6 alkoxy, or C.sub.1 to C.sub.6 aminoalkyl groups; R.sup.3 is selected from a trisubstituted benzene ring; or a 5- or 6-membered heteroaromnatic ring containing 1 or 2 substituents; or a pharmaceutically acceptable salt thereof, in combination with a progestational agent, an estrogen, or both or for the treatment and/or prevention of secondary amenorrhea, dysfunctional bleeding, uterine leiomyomata, endometriosis; polycystic ovary syndrome, carcinomas and adenocarcinomas of the endometrium, ovary, breast, colon, prostate. These combinations may also be used to in methods of contraception, to stimulate food intake or for minimization of side effects or cyclic menstrual bleeding.